codes considered should be included in the text: therefore the table could be deleted. -Sample size: If you were interested in investigating vaccination effectiveness in different subgroups, you should define which subgroups were finally considered and consequently recruiting this number of patients for each subgroup. -Statistical analysis: An adjusted analysis of the vaccine effectiveness should be made in addition to the crude analysis, taking into account variables that could act as confounders. Results of adjusted OR should be shown. Ethical considerations: The type of informed consent obtained should be detailed. Results: You state that four subjects were co-infected, but in table 3 there are 7 cases with co-infection. The information in this table could be included in the text: therefore the table could be deleted.
- Table 4 is difficult to understand. It would be better to put the cases and controls in columns and specify the proportion of vaccinated subjects for cases and controls. -In table 5 there is a variable (deterioration of general condition) that is not included in the Methods section. How was this variable collected? -The results of the adjusted analysis should be included in table 6 Discussion: -On page 18, you state "Due to the lack of precision in the stratified analysis these results can serve only as indications", but in fact you have not made a stratified analysis. You made a crude analysis in different subgroups. Because the sample size was estimated for all the patients, it seems logical that you do not have enough patients to make conclusions in the subgroup analysis. -On page 19, you state: "This was confirmed by the odds ratio of 1 when 0 vaccinated influenza B cases were replaced with 1 case…", but this information and data should be included in table 6 (in a footnote, for example).
-On page 21 you comment "Multiple years are needed to investigate the role of the previous influenza infection as a potential effect modifier for the vaccine effectiveness estimates,…". However, you have information on influenza illness in the previous season and therefore you could include this variable to determine whether vaccine effectiveness differed between those who had influenza disease in the previous season and those who did not.
REVIEWER
Eelko Hak Pharmacy, University Groningen, The Netherlands REVIEW RETURNED 30-Jan-2017 Other papers have suggested that the choice of the control group (all negative for influenza virus infection, non-influenza virus positive and pan-negative) could influence the SIVE estimate. Please elaborate on this in the discussion part.
GENERAL COMMENTS
At line 287-288 it is discussed that the included hospitals "are the main centers where the most severe patients with respiratory conditions are admitted in the Vilnius and Kaunas regions". However, in the previous paper (Gefeinte G et al (2014) ) which estimated the SIVE in the season of 2012-2013 using data from the same hospitals it is stated that "the population captured in our study might be healthier as the patients with the most severe influenza complications might not have been included". Could you please explain this discrepancy and update the paper accordingly if needed?
Minor remarks: -Throughout the paper please update that people are tested positive or negative for an influenza virus infection instead of influenza.
-Line 74: Perhaps include "rates" after mortality -Line 76: Remove "subjects" -Line 82: "cannot be generalized" instead of "could not be 
VERSION 1 -AUTHOR RESPONSE

Comments of Reviewer 1 Response to reviewers' comments
The article "Seasonal influenza vaccine effectiveness against laboratory-confirmed influenza in 2015-16: A hospital-based testnegative case-control study in Lithuania" has been reviewed. The topic of the article (the effectiveness of influenza vaccination in patients admitted to hospital due to severe acute respiratory infection) is of interest as an important problem in infectious disease and public health. I have two main concerns: the small number of subjects included in the study and the lack of adjustment to estimate vaccine effectiveness (see specific comments).
Abstract: The number of subjects included is not shown, and this a very important element in the assessment of the validity of the results.
Number of included subjects is stated in line 35: "Ninety-one (56.4%) of the 163 included subjects were ≥ 65 years old."
Introduction: At the end of this section, the primary objective of the study is stated, but no secondary objective is included. Therefore, I assume that the primary objective is the only objective.
The primary objective was the only objective. We adjusted the text accordingly, lines 104-105: "The objective of this study was to measure SIVE against laboratory-confirmed influenza in patients admitted to hospital due to severe acute respiratory infection (SARI) in Lithuania."
Methods: The study population includes subjects eligible to receive influenza vaccination free of charge. Are healthcare workers and people working in essential services in the community also included in this category? You should state all the population groups in which vaccination is recommended and explain whether vaccination is recommended or compulsory.
The text was adjusted accordingly, lines 113-115: "The study population consisted of 18 years and older individuals with underlying medical conditions, healthy ≥65 years old individuals and pregnant women living in the community, who were admitted to one of the participating sites due to SARI…".
You should state how any contraindications to influenza vaccination were investigated.
Adjusted in the text, lines 116-117: "…with no contra-indication for influenza vaccination, i.e., allergies to influenza vaccine and other adverse events to vaccinations in the past".
The inclusion criteria in table 1 would be better stated in the text: therefore the table could be deleted.
Adjusted in the text, lines 117-125: "Patients were eligible to be included in the study when they were hospitalized for at least 24 h, but not longer than 48 h, had a swab taken ≤7 days after selfreported disease onset, did not test positive and were not hospitalized for any influenza virus in the current season before the inclusion, and were suffering from SARI with at least one of the systemic symptoms (fever, malaise, headache, myalgia) or deterioration of general condition or deterioration of functional status, and at least one of the respiratory symptoms (cough, sore throat, shortness of breath). Patients were not eligible to be included in the study when they were institutionalized, unwilling to participate, not able to communicate, not able and/or willing to give written informed consent."
Was informed consent written? Please, specify. Specified in the text, line 125: "…willing to give written informed consent."
How was the vaccination status of patients Adjusted in the text, line 140: "…vaccination confirmed by their general practitioner? Was this information included in the clinical record or in another specific record?
status was confirmed by their general practitioner (GP) records." Table 2 is very long and probably unnecessary. Information on the codes considered should be included in the text: therefore the table could be deleted. Table 2 was deleted and moved to Appendix 1; information about the chronic conditions was included in the text.
Sample size: If you were interested in investigating vaccination effectiveness in different subgroups, you should define which subgroups were finally considered and consequently recruiting this number of patients for each subgroup.
Adjusted in the text, lines 176-177: "The sample size was estimated for the total sample only. "
We would like to clarify that we performed subgroup analysis for different age groups, as it was a potential confounder. Due to limited sample size, it serves only as an indication.
Statistical analysis: An adjusted analysis of the vaccine effectiveness should be made in addition to the crude analysis, taking into account variables that could act as confounders. Results of adjusted OR should be shown.
We revised the section accordingly, lines 180-182:" The analysis was adjusted for confounding when the variables were associated with both the outcome and the vaccination at alpha level of 10%."
However, as we showed in the results, except for age (18-64 and ≥65 years old), none of the variables were associated with both the outcome and the vaccination at alpha level of 10%, and therefore they were not included in the adjusted multivariable logistic regression analysis. To adjust for age, we performed a stratified by age analysis to indicate the differences. Adjusted according to the reviewer"s comment, lines 202-206: "In addition to influenza, seven subjects were co-infected: two with adenovirus (2.8%), one with coronavirus (1.4%), two with metapneumovirus (2.8%) and two with respiratory syncytial virus (RSV) (2.8%). Other respiratory pathogens isolated from the study participants (n=25) were RSV (6, 3.7%), adenovirus (5, 3.1%), metapneumovirus (5, 3.1%), rhinovirus (6, 3.7%), coronavirus (2, 2.3%) and parainfluenza (1, 0.6%)." Table 4 is difficult to understand. It would be better to put the cases and controls in columns
We would like to clarify that in Table 1 (Table 4 was renamed to Table 1 ) both cases and and specify the proportion of vaccinated subjects for cases and controls.
controls, and the proportion of different factors within the group of cases and the controls are included in the columns. The % of vaccinated subjects within cases and controls is provided for the variable "SIV in 2015-2016 season". Thus, the table allows the comparison between cases and controls.
In table 5 there is a variable (deterioration of general condition) that is not included in the Methods section. How was this variable collected?
Deterioration of general condition is included in the definition of SARI (Methods section, lines 121-122). This variable was collected from the self-reports of the subjects.
The results of the adjusted analysis should be included in table 6 We adjusted the statistical analysis description and the results sections accordingly. We would like to clarify that no variables were associated with both the outcome and the vaccination at alpha level of 10% except for age (18-64 and ≥65 years old), therefore the adjusted analysis was not performed. Instead we performed analysis stratified by age, as this provides an indication of SIVE for different risk groups of interests.
Discussion. On page 18, you state "Due to the lack of precision in the stratified analysis these results can serve only as indications", but in fact you have not made a stratified analysis. You made a crude analysis in different subgroups. Because the sample size was estimated for all the patients, it seems logical that you do not have enough patients to make conclusions in the subgroup analysis.
We performed the analysis stratified by age, which indeed resulted in crude SIVE estimates for different age groups.
We now clarified statistical analysis description and adjusted the results (see a reply to a previous comment), and the discussion. We rephrased the sentence into the following, lines 260-261:
"Due to the lack of precision in the subgroup analysis these results can serve only as indicatory."
On page 19, you state: "This was confirmed by the odds ratio of 1 when 0 vaccinated influenza B cases were replaced with 1 case…", but this information and data should be included in The introduction has been revised.
Line 113-114: Could you explain the influenza vaccination policy in Lithuania? Because why is the sentence added "who were eligible to receive influenza vaccination free of charge"?
We added this information, lines 113-116:
"The study population consisted of 18 years and older individuals with underlying medical conditions, healthy ≥65 years old individuals and pregnant women living in the community, who were admitted to one of the participating sites due to SARI…"
Line 121: For what kind of conditions were people admitted who had at least one of the systemic symptoms etc. "within 48 hours after admission"? Are those subjects admitted for pneumonia or another respiratory disease? Are they admitted for SARI at the hospital (which is stated in line 129-130)?
We rephrased and clarified the text, lines 117-123: "Patients were eligible to be included in the study when they were hospitalized for at least 24 h, but not longer than 48 h, had a swab taken ≤7 days after self-reported disease onset, did not test positive and were not hospitalized for any influenza virus in the current season before the inclusion, and were suffering from SARI with at least one of the systemic symptoms (fever, malaise, headache, myalgia) or deterioration of general condition or deterioration of functional status, and at least one of the respiratory symptoms (cough, sore throat, shortness of breath)."
Line 254-259: The estimated SIVEs are compared here with other studies. However, these studies include other seasons, other countries and in some cases even multiple sites.
We added this information, lines 262-274:
"In our study, SIVE was higher than the midseason estimates against influenza
